Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
461-480 of 1,743 trials

Myelofibrosis: INCB057643 Safety Study

We are testing a new drug, INCB057643, for people with myelofibrosis and other advanced blood cancers. The study focuses on understanding its safety and how well patients tolerate it.

MyelofibrosisMyeloproliferative NeoplasmMyelodysplastic Syndrome>2 yearsSafety phase (I)Hematology

Breast Reconstruction: Goal-Directed Fluid Therapy

We are studying how a specific fluid management approach during DIEP breast reconstruction may reduce swelling and improve healing. This trial aims to see if it helps with better blood flow to the surgical area.

Low Blood Pressure>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsInternal MedicineOtolaryngology

VAXXAIR TRIAL: Comparing Nasal and Injectable Flu Vaccines

We are studying how well a nasal flu vaccine works compared to an injectable one in building immunity. This research aims to find out which method produces a stronger immune response in the body.

Influenza>2 yearsMonitoring phase (IV)6-10 visitsInvestigational MedicinesCost ReimbursementInfectious DiseasesPulmonology

Advanced Solid Tumors: VVD130037 Treatment

We are testing a new drug for patients with advanced solid tumors to see how safe it is and how well it may work against cancer. This study will help us understand its effects on the body and its potential benefits.

Solid TumorSquamous Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Carbetocin Nasal Spray for Hunger in Prader-Willi Syndrome

We are studying the safety of carbetocin nasal spray for people with Prader-Willi Syndrome who experience uncontrollable hunger. The trial also looks at how this treatment may help with anxiety and caregiver challenges.

Hyperphagia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesEndocrinologyPediatrics

Diffuse Large B-cell Lymphoma: Rituximab and Golcadomide Study

We are testing a new combination treatment for older frail patients with Diffuse Large B-cell non-Hodgkin Lymphoma. This study aims to see if it can improve outcomes without traditional chemotherapy.

Diffuse Large B-cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyInternal Medicine

Heart Failure: Colchicine Study

We are investigating whether colchicine can improve health status in people with heart failure compared to a placebo. This study aims to see if it helps patients feel better based on specific health questionnaires.

Heart Failure with Preserved Ejection Fraction>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCardiologyInternal Medicine

Nicotinamide for OPA1 Dominant Optic Atrophy

We are studying whether nicotinamide (vitamin B3) is safe and effective for people with OPA1 Dominant Optic Atrophy. The trial will assess its impact on vision and overall quality of life.

Dominant Optic Atrophy>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementNeurologyOphthalmology

Cell Therapy for Amyotrophic Lateral Sclerosis

We are investigating whether a new cell therapy can help patients with ALS. This study aims to explore its effects on disease progression and quality of life.

Amyotrophic Lateral Sclerosis>2 yearsEfficacy phase (II)Neurology

Cytomegalovirus Treatment: Letermovir and Valganciclovir Combination

We are studying whether a combination of letermovir and valganciclovir helps kidney transplant recipients with CMV infections achieve better viral response than valganciclovir alone.

Cytomegalovirus InfectionKidney Transplant>2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesInfectious DiseasesNephrology

Advanced Solid Tumors: ABBV-400 Treatment

We are evaluating a new treatment for individuals with advanced solid tumors to see how safe it is and if it may help improve their condition.

Locally Advanced or Metastatic Solid Tumors>2 yearsSafety phase (I)Internal MedicineOncology

Becker Muscular Dystrophy: EDG-5506 Treatment Study

We are examining the long-term safety and tolerability of EDG-5506 in adults and adolescents with Becker Muscular Dystrophy. This study aims to understand how well the treatment is tolerated over time.

Becker's Muscular Dystrophy>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Clostridioides difficile Infection: EXL01 Treatment

We are studying a new oral treatment, EXL01, to see if it can help prevent the return of Clostridioides difficile infection in high-risk patients. The trial will evaluate its safety and effectiveness, along with its impact on digestive health and quality of life.

Recurrent Clostridioides difficile Infection>2 yearsSafety phase (I)Efficacy phase (II)Standard MedicinesGastroenterologyInfectious Diseases

Multiple Myeloma: Linvoseltamab Therapy Study

We are examining a new treatment called Linvoseltamab for adults with multiple myeloma that hasn't responded to standard care. The study looks at how it works with other cancer treatments.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)HematologyOncology

Talquetamab: Reducing Oral Side Effects

We are testing ways to lessen taste changes caused by talquetamab in patients undergoing treatment. The goal is to find effective methods to improve the experience for those affected.

Multiple Myeloma>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology

Bladder Cancer: Erdafitinib Delivery System Study

We are testing a new way to deliver Erdafitinib for people with non-muscle-invasive or muscle-invasive bladder cancer. The goal is to see how safe it is and how well it works compared to standard treatments.

Localized Bladder Cancer>2 yearsSafety phase (I)OncologyUrology

B-cell Non-Hodgkin Lymphoma: JNJ-90014496

We are testing a new treatment called JNJ-90014496 for adults with B-cell Non-Hodgkin Lymphoma. The goal is to see how well it works and its safety compared to existing options.

Non-Hodgkin Lymphoma>2 yearsSafety phase (I)Oncology

Breast Cancer Treatment: Chemotherapy vs. Endocrine Therapy

We are studying the effectiveness of chemotherapy compared to endocrine therapy for women with ER-positive HER2-negative metastatic breast cancer. This trial focuses on patients with specific health markers to determine the best treatment option.

Metastatic Breast Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncology

Heart Failure: Optimizing Drug Levels

We are studying how blood levels of heart failure medications affect patient health. This research may help improve treatment plans for individuals with heart failure.

Chronic Heart Failure with Reduced Ejection Fraction>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

MK-5684 Therapies for Advanced Prostate Cancer

We are studying the safety and effectiveness of MK-5684-based treatments for men with metastatic castration-resistant prostate cancer. This research aims to find better options for managing this advanced stage of cancer.

Metastatic Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)Standard MedicinesCost ReimbursementOncologyUrology